Showing 36,281 - 36,300 results of 109,953 for search '(( 5 ((a decrease) OR (mean decrease)) ) OR ( a ((nn decrease) OR (point decrease)) ))', query time: 2.06s Refine Results
  1. 36281
  2. 36282

    Table_1_A 24-h restraint with food and water deprivation: a potential method to establish a model of depression in pigs.pdf by Sen Yang (88300)

    Published 2023
    “…After acute stress, pigs exhibited decreased feed intake and sucrose preference, increased serum COR levels, decreased hippocampal 5-HT levels, and exhibited more fear. …”
  3. 36283
  4. 36284
  5. 36285

    Baseline characteristics of the study sample<sup>β</sup>μ. by Osama Mohamed Ibrahim (12006954)

    Published 2024
    “…The mean time needed to resolve a DRP was shortest in Active Group A (7.3 ±3.5 minutes), followed by Active Group B (9.8 ±4.2 minutes) and the Control Group (9.8 ±5.7 minutes).…”
  6. 36286

    The flow diagram of the study (CONSORT, 2010). by Osama Mohamed Ibrahim (12006954)

    Published 2024
    “…The mean time needed to resolve a DRP was shortest in Active Group A (7.3 ±3.5 minutes), followed by Active Group B (9.8 ±4.2 minutes) and the Control Group (9.8 ±5.7 minutes).…”
  7. 36287

    Purification and Characterization of the Fe<sup>II</sup>- and α-Ketoglutarate-Dependent Xanthine Hydroxylase from <i>Aspergillus nidulans</i><sup>†</sup> by Gabriela M. Montero-Morán (2493271)

    Published 2007
    “…The αKG cosubstrate can be substituted with α-ketoadipate (9-fold decrease in <i>k</i><sub>cat</sub> and 5-fold increase in the <i>K</i><sub>m</sub> compared to those of the normal α-keto acid), while the αKG analogue <i>N</i>-oxalylglycine is a competitive inhibitor (<i>K</i><sub>i</sub> = 0.12 μM). …”
  8. 36288

    Vanadium Oxides on Aluminum Oxide Supports. 3. Metastable κ-Al<sub>2</sub>O<sub>3</sub>(001) Compared to α-Al<sub>2</sub>O<sub>3</sub>(0001) by Tanya K. Todorova (2026051)

    Published 2007
    “…On the α-Al<sub>2</sub>O<sub>3</sub>(0001) surface, the only stable low-coverage VO<i><sub>x</sub></i> species are dimers with V−O<sup>(2)</sup>−Al interface bonds and a defect formation energy of 2.8 eV. …”
  9. 36289

    Sensitivity of the long-term reduction in microfilarial load in individuals under 20 years of age to the assumed rate of decay of vaccine efficacy. by Hugo C. Turner (407442)

    Published 2015
    “…<p>The mean duration of vaccine prophylactic (against incoming L3 larvae) and therapeutic (against microfilariae) activity is 1/the rate of decay (i.e. 5, 10, 20 and 50 years). …”
  10. 36290
  11. 36291
  12. 36292
  13. 36293

    Descriptive statistics. by Mashudu Lucas Bidzha (15183345)

    Published 2023
    “…Results also show that a decrease in under-five mortality is associated with a decline in fertility over the sample period. …”
  14. 36294

    Time courses of evoked VSD response at the stimulation site. by Tamás Dávid Fehérvári (778154)

    Published 2015
    “…Typically, a fast initial increase of fluorescence was followed by a fast decrease, then a slow decrease or slow undershoot below the baseline. …”
  15. 36295
  16. 36296
  17. 36297

    TK1 protein levels do not reflect p-ERK attenuation following inhibition of <sup>V600E</sup>BRAF inhibition in COLO 205 cells. by Eliot T. McKinley (390272)

    Published 2014
    “…<p>COLO 205 cells were collected 48 hours of PLX 4032 exposure at 10 nM, 100 nM, 500 nM, 1 µM, or 5 µM. (<b>A</b>) Western blot analysis demonstrated target inhibition of p-MEK despite increased p-ERK levels. …”
  18. 36298
  19. 36299

    Reaction Mechanism Underlying Pd(II)-Catalyzed Oxidative Coupling of Ethylene and Benzene to Form Styrene: Identification of a Cyclic Mono-Pd<sup>II</sup> Bis-Cu<sup>II</sup> Compl... by Charles B. Musgrave (3071073)

    Published 2022
    “…The PdCu<sub>2</sub>(μ-OAc)<sub>6</sub> cyclic trimer leads to a CMD barrier of 33.5 kcal/mol, while the [Pd­(μ-OAc)<sub>2</sub>]<sub>3</sub> species leads to a larger CMD barrier at >35 kcal/mol. …”
  20. 36300

    Image1_The Activation of PDGFRβ on Mononuclear Stromal/Tumor Cells in Giant Cell Tumor of Bone After Denosumab Treatment. An Immunohistochemical Study of Five Cases.TIF by Imre Antal (733427)

    Published 2022
    “…<p>Due to the relatively high recurrence rate and the destructive nature of the tumor, the treatment of giant cell tumor is still a challenge. Denosumab appeared to be a promising candidate as a therapeutic drug. …”